Regulatory PathRegulatory requirements compared

Active substances

Guaifenesin + Pseudoephedrine

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade nameStrengthForm · routePackPublic priceTypeCompanyStatus
GUAFEDRIN10, 6 mg/mlSyrup · Oral use1 BottleSAR 5.15Generic · OTCRIYADH PHARMAWithdrawn by MAH · Not Marketed
ROBITUSSIN-PE SYRUP20,6 mg/ml,mg/mlSyrup · Oral use1 BottleSAR 6.70NCE · OTCFEREVA RICHMONDWithdrawn by regulatory authority · Not Marketed

US FDA United States — FDA approvals (Drugs@FDA)

ProductStrengthForm · routeApplicantStatusFirst approved
MUCINEX D600MG;60MG; 1.2GM;120MGtablet, extended release · oralRECKITT BENCKISEROver-the-counter22 Jun 2004
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralACTAVIS LABS FLOver-the-counter27 May 2015
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralDR REDDYSOver-the-counter29 Dec 2017
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralAUROBINDO PHARMA LTDOver-the-counter25 Mar 2020
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralSUN PHARM INDS INCOver-the-counter28 Apr 2020
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralL PERRIGO COOver-the-counter1 Feb 2022
GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE600MG;60MG; 1.2GM;120MGtablet, extended release · oralGRANULESDiscontinued22 Aug 2022

Prices — United States and England

SourceProduct as listedPriceUnit / packDate
US NADACGUAIFENESIN-PSE ER 1200-120 MG$0.42347per EA23 Sep 2026
US NADACGUAIFENESIN-PSE ER 600-60 MG$0.38412per EA23 Sep 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.